NN 9709

Drug Profile

NN 9709

Alternative Names: NN9709

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 17 Feb 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route) prior to February 2016 (Novo Nordisk's pipeline, February 2016 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top